Table 1 A complete list of inclusion and exclusion criteria for the EVRAAS study

1. Patients of the Clinic of Dermatology, Sexually Transmitted Diseases and Immunodermatology, Nicolaus Copernicus University, Faculty of Medicine in Bydgoszcz

2. Provision of an informed consent form prior to any study procedures

3. Diagnosis of NSV acrofacial vitiligo with upper and lower limbs involvement

4. Active vitiligo, defined as appearance of new areas of depigmentation or progression of existing areas of depigmentation within 3 months preceding screening

5. Male or nonpregnant female patients aged 18 to 80 years

6. Confirmed valid health insurance

1. Pregnancy or breastfeeding

2. Diagnosis of segmental, mixed, unclassified, or undefined vitiligo

3. Hypersensitivity to simvastatin or atorvastatin

4. Any statin use within 8 weeks preceding eligibility screening

5. Systemic immunosuppressive/immunomodulating treatment (i.e., cyclosporine A, corticosteroids) within 4 weeks preceding eligibility screening or azathioprine, methotrexate, mycophenolate mofetil, or Janus kinase (JAK) inhibitors within 8 weeks preceding eligibility screening

6. Phototherapy due to vitiligo or any other medical conditions within the 4-week period preceding eligibility screening

7. Any topical or systemic additional vitiligo treatment (e.g., antioxidants, Ginkgo biloba, dermocosmetics) within 4 weeks preceding screening

8. Surgical treatment of vitiligous lesions within the past 4 weeks

9. Decompensated autoimmune or internal diseases

10. Alcohol or drug abuse

11. Skin malignancies (current or a history of skin malignancy within 5 years preceding screening)

12. Presence of skin characteristics that may interfere with study assessments

13. Patients currently participating in any other clinical study

14. Uncooperative patients